New Retina Radio
10.09.25
How do retina specialists first broach the topic of complement inhibition for GA therapy? In episode 1 of this miniseries, moderator Charles Wykoff, MD, PhD, speaks with Maryam Ghiassi, MD, MHS, and Matthew Cunningham, MD, about timing treatment conversations, managing patients with one good and one bad eye, and addressing whether patients can maintain driving. 
View full description +
Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.
Subscribe
11.17.25
The Nuts and Bolts of GA Therapy: Wrapping Up the ConversationCharles Wykoff, MD, PhD; Sruthi Arepalli, MD; and Kenneth Fan, MD, MBA
Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.
11.13.25
AAO '25: GLP-1s and AMD, and Parity in Retina CareAleksandra Rachitskaya, MD; and Julia Haller, MD
Editorially independent content, supported by Genentech.
11.10.25
Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLERahul Khurana, MD; and Arshad Khanani, MD, MA
Editorially independent content, supported by Genentech.
11.06.25
AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt DiseasePeter Kaiser, MD; and Michel Michaelides, MD
Editorially independent content, supported by Genentech.
11.03.25
The Nuts and Bolts of GA Therapy: The Discussions ContinueCharles Wykoff, MD, PhD; Hasenin Al-khersan, MD; and Nakul Singh, MD
Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.
10.23.25
Late-Breaking Talks at AAO '25: Gene Therapy for RP and NPDRAllen Ho, MD; and Charles Wykoff, MD, PhD
Editorially independent content, supported by Genentech.
10.10.25
New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient CareNiki Kothari, MD; Jesse Sengillo, MD; and Nicholas Farber, MD
Editorially Independent Content Supported by Genentech
10.09.25
The Nuts and Bolts of GA Therapy: The Opening SessionsCharles Wykoff, MD, PhD; with Maryam Ghiassi, MD, MHS, and Matthew Cunningham, MD
Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.
Show More